Mail

In "The skinny fat ," ¹ Bruce Spiegelman tells us he is working with the Broad Institute to screen every FDA-approved drug for possible effects on a "brown-fat molecule," PRDM16, reasoning that drugs that act on this molecule might also trigger weight loss. Wouldn't it be smart to determine whether any of these FDA-approved drugs are associated with significant weight loss before starting the screening campaign at the molecular level for PRDM16?


	The article you are attempting to read is Premium content which is only available to our online subscribers.

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today